Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
ASCO 2024: Latest Data in Melanoma
Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.
Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.
Dr Lipson provides insights surrounding combination therapies in melanoma management.
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose
3
United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF
4
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
5